路透伦敦8月1日 - 辉瑞PFE.N及其德国合作伙伴BioNTech22UAy.DE周五在伦敦上诉法院推翻了关于其COVID-19疫苗侵犯莫德纳公司MRNA.O一项专利的裁决，但最终败诉。
去年，高等法院裁定 (link)，莫德纳有关信使RNA(mRNA) 技术（该技术是其COVID-19疫苗的基础）的一项专利有效，辉瑞和BioNTech的Comirnaty疫苗侵犯了该专利，这意味着莫德纳有权就2022年3月以后的销售获得赔偿。
辉瑞和莫德纳曾上诉 (link)，试图推翻这一判决，认为莫德纳开发的mRNA技术是对之前工作的显而易见的发展，因此专利无效。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.